Weighing In On DPP-IV Inhibitors: Galvus, Januvia Both Highlight Weight Profiles
This article was originally published in The Pink Sheet Daily
Executive Summary
Data presented on the competing dipeptidyl peptidase IV inhibitors from Novartis and Merck at the American Diabetes Association similarly tout weight loss and other side effect advantages versus standard type 2 diabetes drugs.